SAN JOSE, Calif., March 9, 2018 /PRNewswire/ -- ITUS
Corporation (NASDAQ: ITUS) today announced that John Roop, Senior Vice President of Engineering
is scheduled to present on Friday March 16,
2018, at 4:30 p.m. China
Standard Time, 4:30 a.m. Eastern Standard
Time, at the 2018 Inaugural China Healthcare Investment
& Partnering Symposium (CHIPS) in Hangzhou, China.
"We are pleased to present at this conference that is expected
to bring together over 1,000 Asian investors and strategic
partners. This conference provides us a unique opportunity to
provide exposure for our company and technologies to a global
audience," said John Roop, Senior
Vice President of Engineering of ITUS Corporation.
The China Healthcare Investment & Partnering Symposium is
hosted by TPP Healthcare and supported by a leading investment bank
B.Riley FBR, in conjunction with the Chinese Pharmaceutical
Enterprise Association (CPEA), the leading association of
healthcare companies with over 3,000 members.
For more information on the conference agenda, please access:
https://www.meetmax.com/sched/event_47969/~public/conference_home.html.
ITUS Corporation
ITUS, a cancer-focused biotechnology company, is harnessing the
body's immune system in the fight against cancer. Its wholly
owned subsidiary, Anixa Diagnostics Corporation, is developing the
Cchek™ platform, a series of non-invasive blood tests for the early
detection of solid tumor based cancers, which is based on the
body's immunological response to the presence of a
malignancy. Its majority owned subsidiary, Certainty
Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs
which genetically engineer a patient's own immune cells to fight
cancer. ITUS also continually examines emerging technologies
in complementary or related fields for further development and
commercialization. Additional information is available at
www.ITUScorp.com.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect ITUS
Corporation's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include,
but are not limited to, those factors set forth in "Item 1A - Risk
Factors" and other sections of our most recent Annual Report on
Form 10-K as well as in our Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. We undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except
as required by law. You are cautioned not to unduly rely on
such forward-looking statements when evaluating the information
presented in this press release.
ITUS Corporation: FOCUSED ON INNOVATION™
View original content with
multimedia:http://www.prnewswire.com/news-releases/itus-corporation-to-present-at-the-2018-inaugural-china-healthcare-investment--partnering-symposium-chips-300611240.html
SOURCE ITUS Corporation